ACADIA PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
ACADIA PHARMACEUTICALS INC. (ACAD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $13.25 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-28.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2024-02-28
- ACADIA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $13.25, a 3.00% decline from fiscal 2022.
- ACADIA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $13.66, a 43.25% decline from fiscal 2021.
- ACADIA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $24.07, a 0.37% decline from fiscal 2020.
- ACADIA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $24.16, a 51.28% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|
| 2023-12-31 | $13.25 10-K · filed 2024-02-28 |
| 2022-12-31 | $13.66 10-K · filed 2024-02-28 |
| 2021-12-31 | $24.07 10-K · filed 2024-02-28 |
| 2020-12-31 | $24.16 10-K · filed 2023-02-28 |
| 2019-12-31 | $15.97 10-K · filed 2022-03-01 |
| 2018-12-31 | $12.14 10-K · filed 2021-02-25 |
| 2017-12-31 | $21.11 10-K · filed 2020-02-27 |
| 2016-12-31 | $17.65 10-K · filed 2019-02-27 |
| 2015-12-31 | $25.80 10-K · filed 2018-02-27 |
| 2014-12-31 | $18.90 10-K · filed 2017-02-28 |
| 2013-12-31 | $12.66 10-K · filed 2016-02-29 |
| 2012-12-31 | $1.51 10-K · filed 2015-02-26 |
| 2011-12-31 | $1.25 10-K · filed 2014-02-27 |
| 2010-12-31 | $1.13 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |